MEDPLUS Q3 FY26 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
MedPlus reported a strong Q3 FY26 with revenue of INR 18,061M, driven by 10%+ SSSG, 182 net new stores, and robust diagnostics growth. Margins were stable despite a one-time labor code charge. Key positives include successful incentive restructuring, strong private label non-pharma growth, working capital improvement, and confidence in the margin expansion path. The call conveyed operational execution strength and a clear strategy focused on private label mix and store-level productivity.
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted strong store additions (228 gross, 182 net), revenue growth to INR 18,061M, and improved diagnostics profitability (15.5% EBITDA margin). Mentioned one-time labor code charge but overall showed operational progress.
- Q&A Session: Good — Q&A was substantive with multiple analyst questions on SSSG drivers, margin sustainability, private label mix, and expansion plans. Management provided direct, quantified answers on incentive changes, margin profiles, and growth levers, expressing confidence in reaching 6% pharmacy operating EBITDA
Revenue Growth Drivers
- Incentive structure change to focus on total store sales (branded + private label).
- Private label non-pharma (FMCG) sales growth (~48%).
- Store network expansion (net add 182 stores in Q3).
Growth vs Margin Focus
Management is driving store expansion (growth) while simultaneously focusing on private label mix, especially high-margin non-pharma, and operational efficiencies to improve profitability.
About MedPlus Health Services Limited
MedPlus Health Services Limited (MEDPLUS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.